Atomo Diagnostics Ltd. (AT1) Price & Analysis

Compare

7 Followers

AT1 Stock Chart & Stats

AU$0.04

>-AU$0.01(-5.00%)

At close: Jan 09 4:00 PM EST

AU$0.04

>-AU$0.01(-5.00%)

Day’s Range― - ―

52-Week RangeAU$0.01 - AU$0.05

Previous CloseN/A

Volume312.94K

Average Volume (3M)1.80M

Market Cap

AU$34.03M

Enterprise ValueAU$26.94M

Total Cash (Recent Filing)AU$3.22M

Total Debt (Recent Filing)AU$185.10K

Price to Earnings (P/E)―

Beta0.32

Next Earnings

Apr 23, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding810,175,300

10 Day Avg. Volume984,499

30 Day Avg. Volume1,797,539

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)1.30

Price to Sales (P/S)2.39

P/FCF Ratio-4.55

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Integrated RDT PlatformAtomo’s proprietary integrated blood‑collection and RDT device is a durable business asset: it creates a focused B2B hardware revenue stream selling devices to diagnostic manufacturers and public testing programs, supporting recurring unit sales as partners scale test kit volumes.

Low Financial LeverageVery low leverage gives Atomo financial flexibility over the medium term, reducing interest burden and easing ability to raise incremental capital or fund R&D/manufacturing scale without large fixed financing costs, which supports resilience while revenue recovers.

Relatively High Gross MarginA near-50% gross margin on device sales implies strong unit economics at the product level. If revenue stabilizes or grows, these product margins can generate operating leverage and faster recovery of fixed costs, improving long‑term profitability potential.

Bears Say

Declining RevenueContinued revenue decline undermines scale for a hardware supplier: lower volumes reduce bargaining power with buyers, raise per‑unit fixed cost absorption, and weaken the core B2B sales pipeline, making recovery and margin improvement harder without new partner wins.

Deeply Negative ProfitabilityExtremely negative EBIT and net margins reflect structural unprofitability that erodes equity and limits reinvestment. Persistent operating losses constrain strategic initiatives, make talent retention and supply relationships harder, and increase reliance on external funding.

Deteriorating Cash GenerationWorsening cash flow and negative operating cash generation create runway risk for a hardware manufacturer that needs working capital for production and program supply. Continued cash burn raises financing needs and execution risk over the next several months.

Atomo Diagnostics Ltd. News

Atomo Wins A$630,000 Order for Government-Backed HIV Self-Testing Program

The latest update is out from Atomo Diagnostics Ltd. ( ($AU:AT1) ). Atomo Diagnostics has secured a material...

17d ago

AT1

Atomo Wins Second Major Global Fund–Backed Order for HIV Self-Tests

Atomo Diagnostics Ltd. ( ($AU:AT1) ) has shared an announcement. Atomo Diagnostics has secured a A$416,000 purchase order...

24d ago

AT1

Atomo Diagnostics Sets Date for Q2 FY26 Results and Investor Webinar

Atomo Diagnostics Ltd. ( ($AU:AT1) ) has provided an announcement. Atomo Diagnostics has scheduled the release of its...

1M ago

AT1

Atomo Diagnostics Wins Exclusive Global Licence for Rapid Liver Function Test on Pascal Platform

Atomo Diagnostics Ltd. ( ($AU:AT1) ) has shared an announcement. Atomo Diagnostics has secured an exclusive global licence...

1M ago

AT1

Atomo Wins $502,000 HIV Self-Test Order Backed by Global Fund

Atomo Diagnostics Ltd. ( ($AU:AT1) ) just unveiled an announcement. Atomo Diagnostics Limited has secured a material purchase...

1M ago

AT1

Atomo Diagnostics Grants Options to Director Following Shareholder Approval

An announcement from Atomo Diagnostics Ltd. ( ($AU:AT1) ) is now available. Atomo Diagnostics Ltd. announced a change...

2M ago

AT1

Atomo Diagnostics Issues New Equity Securities Under Employee Incentive Scheme

Atomo Diagnostics Ltd. ( ($AU:AT1) ) has provided an announcement. Atomo Diagnostics Ltd. has announced the issuance of...

2M ago

AT1

Atomo Diagnostics Addresses ASX Query on Unusual Trading Activity

Atomo Diagnostics Ltd. ( ($AU:AT1) ) has issued an update. Atomo Diagnostics Ltd. has responded to an ASX...

3M ago

AT1

Atomo Diagnostics Adopts Amended Constitution

The latest announcement is out from Atomo Diagnostics Ltd. ( ($AU:AT1) ). Atomo Diagnostics Ltd. announced the adoption...

4M ago

AT1

Atomo Diagnostics Reports Successful 2025 AGM Results

Atomo Diagnostics Ltd. ( ($AU:AT1) ) just unveiled an announcement. Atomo Diagnostics Limited announced the results of its...

4M ago

AT1

AT1 FAQ

What was Atomo Diagnostics Ltd.’s price range in the past 12 months?

Atomo Diagnostics Ltd. lowest share price was AU$0.01 and its highest was AU$0.05 in the past 12 months.

What is Atomo Diagnostics Ltd.’s market cap?

Atomo Diagnostics Ltd.’s market cap is AU$34.03M.

When is Atomo Diagnostics Ltd.’s upcoming earnings report date?

Atomo Diagnostics Ltd.’s upcoming earnings report date is Apr 23, 2026 which is in 60 days.

How were Atomo Diagnostics Ltd.’s earnings last quarter?

Currently, no data Available

Is Atomo Diagnostics Ltd. overvalued?

According to Wall Street analysts Atomo Diagnostics Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Atomo Diagnostics Ltd. pay dividends?

Atomo Diagnostics Ltd. does not currently pay dividends.

What is Atomo Diagnostics Ltd.’s EPS estimate?

Atomo Diagnostics Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Atomo Diagnostics Ltd. have?

Atomo Diagnostics Ltd. has 810,175,300 shares outstanding.

What happened to Atomo Diagnostics Ltd.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Atomo Diagnostics Ltd.?

Currently, no hedge funds are holding shares in AU:AT1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Atomo Diagnostics Ltd. Stock Smart Score

Neutral

Blogger Sentiment

Bullish

AU:AT1 Sentiment 100%
Sector Average 70%

Technicals

Fundamentals

Return on Equity

-58.27%

Trailing 12-Months

Asset Growth

-18.47%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Atomo Diagnostics Ltd.

Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. It offers rapid diagnostic test devices for COVID-19, HIV screening, pregnancy test, and respiratory test. The company was incorporated in 2010 and is headquartered in Leichhardt, Australia.